Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. META
9. AMC
10. ACN

Go back to Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Delayed: 244.32 +4.76 (1.99%)
Previous Close $239.56    52 Week High $109.10 
Open $240.37    52 Week Low $31.38 
Day High $247.10    P/E N/A 
Day Low $237.97    EPS $-1.45 
Volume 1,152,873       

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Delayed: 244.32 +4.76 (1.99%)
Previous Close $239.56    52 Week High $109.10 
Open $240.37    52 Week Low $31.38 
Day High $247.10    P/E N/A 
Day Low $237.97    EPS $-1.45 
Volume 1,152,873       

SANOFI (NASDAQ: SNY) Delayed: 42.50 +0.02 (0.05%)
Previous Close $42.48    52 Week High $44.76 
Open $42.64    52 Week Low $36.81 
Day High $42.78    P/E N/A 
Day Low $42.47    EPS $0.00 
Volume 2,484,466